<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">urmj</journal-id><journal-title-group><journal-title xml:lang="ru">Уральский медицинский журнал</journal-title><trans-title-group xml:lang="en"><trans-title>Ural Medical Journal</trans-title></trans-title-group></journal-title-group><issn pub-type="epub">2949-4389</issn><publisher><publisher-name>Ural State Medical University</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.52420/2071-5943-2022-21-5-26-32</article-id><article-id custom-type="elpub" pub-id-type="custom">urmj-1081</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ПАТОФИЗИОЛОГИЯ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>PATHOPHYSIOLOGY</subject></subj-group></article-categories><title-group><article-title>Влияние системного применения озона на окислительную модификацию липидов и белков в толстой кишке при экспериментальном колите</article-title><trans-title-group xml:lang="en"><trans-title>Effect of systemic ozone use on oxidative modification of lipids and proteins in the colon in experimental colitis</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-6487-9083</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Осиков</surname><given-names>М. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Osikov</surname><given-names>M. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Михаил Владимирович Осиков, доктор медицинских наук, профессор</p><p>Челябинск</p></bio><bio xml:lang="en"><p>Mikhail V. Osikov, Doctor of Science (Medicine), Professor</p><p>Chelyabinsk</p></bio><email xlink:type="simple">prof.osikov@yandex.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-8403-8599</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Кайгородцева</surname><given-names>Н. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Kaygorodtseva</surname><given-names>N. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Наталья Васильевна Кайгородцева, ассистент кафедры</p><p>Челябинск</p></bio><bio xml:lang="en"><p>Natalia V. Kaygorodtseva, Department Assistant</p><p>Chelyabinsk</p></bio><email xlink:type="simple">nkaigorodceva@yandex.ru</email><xref ref-type="aff" rid="aff-2"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>Южно-Уральский государственный медицинский университет; Челябинская областная клиническая больница</institution><country>Россия</country></aff><aff xml:lang="en"><institution>South Ural State Medical University; Chelyabinsk Regional Clinical Hospital</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-2"><aff xml:lang="ru"><institution>Южно-Уральский государственный медицинский университет</institution><country>Россия</country></aff><aff xml:lang="en"><institution>South Ural State Medical University</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2022</year></pub-date><pub-date pub-type="epub"><day>04</day><month>11</month><year>2022</year></pub-date><volume>21</volume><issue>5</issue><fpage>26</fpage><lpage>32</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Осиков М.В., Кайгородцева Н.В., 2022</copyright-statement><copyright-year>2022</copyright-year><copyright-holder xml:lang="ru">Осиков М.В., Кайгородцева Н.В.</copyright-holder><copyright-holder xml:lang="en">Osikov M.V., Kaygorodtseva N.V.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.umjusmu.ru/jour/article/view/1081">https://www.umjusmu.ru/jour/article/view/1081</self-uri><abstract><p>Введение. Процессы свободно-радикального окисления играют значимую роль в патогенезе воспалительных заболеваний кишечника. Цель работы – изучить клинический статус, содержание продуктов перекисного окисления липидов, окислительной модификации белков в очаге повреждения толстой кишки при оксазолон-индуцированном колите (ОИК) в условиях внутрибрюшинного применения озона. Материалы и методы. На крысах линии Wistar моделировали ОИК с использованием раствора оксазолона. Озонокислородную смесь (ОКС) вводили внутрибрюшинно один раз в сутки шесть дней. Клинику оценивали по индексу активности болезни (DAI), в гомогенате толстой кишки определяли содержание продуктов перекисного окисления липидов (ПОЛ) и окислительной модификации белков (ОМБ). Результаты. При ОИК повышается DAI, в гомогенате толстой кишки увеличивается содержание в гептановой фазе уровня первичных и вторичных продуктов; в изопропанольной фазе увеличивался уровень вторичных продуктов и конечных продуктов. В условиях внутрибрюшинного применения озона снижается DAI, в гомогенате толстой кишки повышается на вторые сутки уровень изопропанолрастворимых первичных, вторичных, конечных продуктов ПОЛ, снижается на шестые сутки уровень гептан- и изопропанолрастворимых первичных, вторичных, конечных продуктов ПОЛ, на четвертые, шестые сутки снижаются ранние и поздние продукты ОМБ. Выявлена умеренная и заметная по шкале Чеддока связь между DAI и содержанием в гомогенате толстой кишки продуктов ПОЛ и ОМБ преимущественно на шестые сутки ОИК в условиях внутрибрюшинного применения озона. Обсуждение. Повышение содержания в очаге повреждения толстой кишки продуктов ПОЛ и ОМБ после применения озона, вероятно, обусловлено его опосредованным действием (через активацию АФК) и способностью выступать в роли окислителя липидов и белков клеток слизистой оболочки толстой кишки. Выводы. Зафиксированные при ОИК положительные эффекты внутрибрюшинного применения озона в составе ОКС являются основанием для дальнейшего исследования в изучении механизма протекторного действия озона с возможностью его применения в клинических условиях при воспалительных заболеваниях кишечника.</p></abstract><trans-abstract xml:lang="en"><p>Introduction. The processes of free radical oxidation play a significant role in the pathogenesis of inflammatory bowel diseases. The aim of the work was to study the clinical status, the content of lipid peroxidation products, oxidative modification of proteins in the lesion of the colon in oxazole-induced colitis (OIC) under conditions of intraperitoneal application of ozone. Materials and methods. Wistar rats were modeled for OIC using oxazolone solution. Ozone-oxygen mixture (OX) was injected intraperitoneally once a day for six days. The clinic was assessed by disease activity index (DAI), the content of products of lipid peroxidation (LPO) and oxidative modification of proteins (OMB) was determined in colonic homogenate. Results. Under OIK DAI increases, the level of primary and secondary products in the heptane phase increases in the colonic homogenate; the level of secondary products and end products increased in the isopropanol phase. Under conditions of intraperitoneal application of ozone, DAI decreased, the level of isopropanol-soluble primary, secondary, final LPO products increased in colon homogenate on the 2nd day, the level of heptane- and isopropanol-soluble primary, secondary, final LPO products decreased on the 6th day, early and late LPO products decreased on the 4th, 6th day. We found a moderate and significant relationship on the Cheddock scale between DAI and the content of LPO and OMB products in the colonic homogenate mainly on day 6 of OIC under conditions of intraperitoneal application of ozone. Discussion. The increased content of LPO and OMB products in the lesion of the colon after the use of ozone is probably due to its mediated action (through the activation of ROS) and its ability to act as an oxidant of lipids and proteins of the cells of the mucosa of the colon. Conclusions. The positive effects of intraperitoneal application of ozone in OIC are the basis for further research in studying the mechanism of the protective effect of ozone with the possibility of further application in clinical conditions in inflammatory bowel diseases.</p></trans-abstract><kwd-group xml:lang="ru"><kwd>перекисное окисление липидов</kwd><kwd>окислительная модификация белков</kwd><kwd>экспериментальный колит</kwd><kwd>озон</kwd></kwd-group><kwd-group xml:lang="en"><kwd>lipid peroxidation</kwd><kwd>oxidative modification of proteins</kwd><kwd>experimental colitis</kwd><kwd>ozone</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Bek S., Nielsen J.V., Bojesen A.B. et al. Systematic review: genetic biomarkers associated with anti-TNF treatment response in inflammatory bowel diseases. Aliment Pharmacol Ther. 2016;44(6):554–567. https://doi.org/10.1111/apt.13736.</mixed-citation><mixed-citation xml:lang="en">Bek S., Nielsen J.V., Bojesen A.B. et al. Systematic review: genetic biomarkers associated with anti-TNF treatment response in inflammatory bowel diseases. Aliment Pharmacol Ther. 2016;44(6):554–567. https://doi.org/10.1111/apt.13736.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Burisch J., Munkholm P. The epidemiology of inflammatory bowel disease. Scand J Gastroenterol. 2015;50(8):942–951. https://doi.org/10.3109/00365521.2015.1014407.</mixed-citation><mixed-citation xml:lang="en">Burisch J., Munkholm P. The epidemiology of inflammatory bowel disease. Scand J Gastroenterol. 2015;50(8):942–951. https://doi.org/10.3109/00365521.2015.1014407.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Su H.J., Chiu Y.T., Chiu C.T. et al. Inflammatory bowel disease and its treatment in 2018: Global and Taiwanese status updates. J Formos Med Assoc. 2019;118(7):1083–1092. https://doi.org/10.1016/j.jfma.2018.07.005.</mixed-citation><mixed-citation xml:lang="en">Su H.J., Chiu Y.T., Chiu C.T. et al. Inflammatory bowel disease and its treatment in 2018: Global and Taiwanese status updates. J Formos Med Assoc. 2019;118(7):1083–1092. https://doi.org/10.1016/j.jfma.2018.07.005.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Белоусова Е.А., Абдулганиева Д.И., Алексеева О.П. с соавт. Социально-демографическая характеристика, особенности течения и варианты лечения воспалительных заболеваний кишечника в России. Результаты двух многоцентровых исследований. Альманах клинической медицины. 2018;46(5):445–463. https://doi.org/10.18786/2072-0505-2018-46-5-445-463.</mixed-citation><mixed-citation xml:lang="en">Белоусова Е.А., Абдулганиева Д.И., Алексеева О.П. с соавт. Социально-демографическая характеристика, особенности течения и варианты лечения воспалительных заболеваний кишечника в России. Результаты двух многоцентровых исследований. Альманах клинической медицины. 2018;46(5):445–463. https://doi.org/10.18786/2072-0505-2018-46-5-445-463.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Himuro H. The effect of ozone on colonic epithelial cells. Kurume Med J. 2018;64(4):75–81. https://doi.org/10.2739/kurumemedj.MS644002.</mixed-citation><mixed-citation xml:lang="en">Himuro H. The effect of ozone on colonic epithelial cells. Kurume Med J. 2018;64(4):75–81. https://doi.org/10.2739/kurumemedj.MS644002.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Wallace K.L., Zheng L.B., Kanazawa Y., Shih D.Q. Immunopathology of inflammatory bowel disease. World Journal of Gastroenterology. 2014;20(1):6–21. https://doi.org/10.3748/wjg.v20.i1.6.</mixed-citation><mixed-citation xml:lang="en">Wallace K.L., Zheng L.B., Kanazawa Y., Shih D.Q. Immunopathology of inflammatory bowel disease. World Journal of Gastroenterology. 2014;20(1):6–21. https://doi.org/10.3748/wjg.v20.i1.6.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Alzoghaibi M.A. Concepts of oxidative stress and antioxidant defense in Crohn’s disease. World Journal of Gastroenterology. 2013;19(39):6540–6547. https://doi.org/10.3748/wjg.v19.i39.6540.</mixed-citation><mixed-citation xml:lang="en">Alzoghaibi M.A. Concepts of oxidative stress and antioxidant defense in Crohn’s disease. World Journal of Gastroenterology. 2013;19(39):6540–6547. https://doi.org/10.3748/wjg.v19.i39.6540.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Tian T., Wang Z., Zhang J. Pathomechanisms of oxidative stress in inflammatory bowel disease and potential antioxidant therapies. Oxid. Med. Cell. Longev. 2017;2017:4535194. https://doi.org/10.1155/2017/4535194.</mixed-citation><mixed-citation xml:lang="en">Tian T., Wang Z., Zhang J. Pathomechanisms of oxidative stress in inflammatory bowel disease and potential antioxidant therapies. Oxid. Med. Cell. Longev. 2017;2017:4535194. https://doi.org/10.1155/2017/4535194.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Assadsangabi A., Evans C.A., Corfe B.M., Lobo A. Application of Proteomics to Inflammatory Bowel Disease Research: Current Status and Future Perspectives. Gastroenterol Res Pract. 2019;2019:1426954.</mixed-citation><mixed-citation xml:lang="en">Assadsangabi A., Evans C.A., Corfe B.M., Lobo A. Application of Proteomics to Inflammatory Bowel Disease Research: Current Status and Future Perspectives. Gastroenterol Res Pract. 2019;2019:1426954.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Titz B., Gadaleta R.M., Lo Sasso G. et al. Proteomics and Lipidomics in Inflammatory Bowel Disease Research: From Mechanistic Insights to Biomarker Identification. Int J Mol Sci. 2018;19(9):2775–2796. https://doi.org/10.3390/ijms19092775.</mixed-citation><mixed-citation xml:lang="en">Titz B., Gadaleta R.M., Lo Sasso G. et al. Proteomics and Lipidomics in Inflammatory Bowel Disease Research: From Mechanistic Insights to Biomarker Identification. Int J Mol Sci. 2018;19(9):2775–2796. https://doi.org/10.3390/ijms19092775.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Ashton J.J., Mossotto E., Ennis S., Beattie R.М. Personalising medicine in inflammatory bowel disease-current and future perspectives. Transl Pediatr. 2019;8(1):56–69. https://doi.org/10.21037/tp.2018.12.03.</mixed-citation><mixed-citation xml:lang="en">Ashton J.J., Mossotto E., Ennis S., Beattie R.М. Personalising medicine in inflammatory bowel disease-current and future perspectives. Transl Pediatr. 2019;8(1):56–69. https://doi.org/10.21037/tp.2018.12.03.</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Mittal M., Siddiqui M.R. Reactive Oxygen Species in Inflammation and Tissue Injury. Antioxidants &amp; Redox Signaling. 2014;20(7):1126–1167.</mixed-citation><mixed-citation xml:lang="en">Mittal M., Siddiqui M.R. Reactive Oxygen Species in Inflammation and Tissue Injury. Antioxidants &amp; Redox Signaling. 2014;20(7):1126–1167.</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Bocci V.A. Scientific and medical aspects of ozone therapy. State of the art. Archives of medical research. 2006;37:425–435.</mixed-citation><mixed-citation xml:lang="en">Bocci V.A. Scientific and medical aspects of ozone therapy. State of the art. Archives of medical research. 2006;37:425–435.</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Siniscalco D., Trotta M.C., Brigida A.L. et al. Intraperitoneal Administration of Oxygen/Ozone to Rats Reduces the Pancreatic Damage Induced by Streptozotocin. Biology (Basel). 2018;7(1).</mixed-citation><mixed-citation xml:lang="en">Siniscalco D., Trotta M.C., Brigida A.L. et al. Intraperitoneal Administration of Oxygen/Ozone to Rats Reduces the Pancreatic Damage Induced by Streptozotocin. Biology (Basel). 2018;7(1).</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Bai Z., Li H., Guo X. et al. Successful treatment of acute-on-chronic liver failure and hemolytic anemia with hepatoprotective drugs in combination with intravenous ozone without steroids: A case report. Intractable &amp; rare diseases research. 2018;7(3):204–208.</mixed-citation><mixed-citation xml:lang="en">Bai Z., Li H., Guo X. et al. Successful treatment of acute-on-chronic liver failure and hemolytic anemia with hepatoprotective drugs in combination with intravenous ozone without steroids: A case report. Intractable &amp; rare diseases research. 2018;7(3):204–208.</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Директива 2010/63/EU Европейского парламента и Совета Европейского Союза от 22 сентября 2010 года по охране животных, используемых в научных целях. СПб.: 2012.</mixed-citation><mixed-citation xml:lang="en">Директива 2010/63/EU Европейского парламента и Совета Европейского Союза от 22 сентября 2010 года по охране животных, используемых в научных целях. СПб.: 2012.</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Turner P.V., Brab Th., Pekow C., Vasbinde M.A. Administration of substances to laboratory animals: routes of administration and factors to consider. J. Am. Assoc. Lab. Anim. Sci. 2011;50(5):600–613.</mixed-citation><mixed-citation xml:lang="en">Turner P.V., Brab Th., Pekow C., Vasbinde M.A. Administration of substances to laboratory animals: routes of administration and factors to consider. J. Am. Assoc. Lab. Anim. Sci. 2011;50(5):600–613.</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Best W.R., Becktel J.M., Singleton J.W., Kern F.Jr. Development of a Crohn's disease activity index. National Cooperative Crohn's Disease Study. Gastroenterology. 1976;70(3):439–444.</mixed-citation><mixed-citation xml:lang="en">Best W.R., Becktel J.M., Singleton J.W., Kern F.Jr. Development of a Crohn's disease activity index. National Cooperative Crohn's Disease Study. Gastroenterology. 1976;70(3):439–444.</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Cooper H.S., Murthy S.N., Shah R.S., Sedergran D.J. Clinicopathologic study of dextran sulfate sodium experimental murine colitis. Laboratory investigation. 1993;69(2):238–249.</mixed-citation><mixed-citation xml:lang="en">Cooper H.S., Murthy S.N., Shah R.S., Sedergran D.J. Clinicopathologic study of dextran sulfate sodium experimental murine colitis. Laboratory investigation. 1993;69(2):238–249.</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Kim J.J., Shajib M.S., Manocha M.M., Khan W.I. Investigating intestinal inflammation in DSS-induced model of IBD. Journal of visualized experiments. 2012;60. https://doi.org/10.3791/3678.</mixed-citation><mixed-citation xml:lang="en">Kim J.J., Shajib M.S., Manocha M.M., Khan W.I. Investigating intestinal inflammation in DSS-induced model of IBD. Journal of visualized experiments. 2012;60. https://doi.org/10.3791/3678.</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">Hughes A. A simplified benzidine test with an evaluation of some faecal occult blood tests. British medical journal. 1952;2(4791):970–975.</mixed-citation><mixed-citation xml:lang="en">Hughes A. A simplified benzidine test with an evaluation of some faecal occult blood tests. British medical journal. 1952;2(4791):970–975.</mixed-citation></citation-alternatives></ref><ref id="cit22"><label>22</label><citation-alternatives><mixed-citation xml:lang="ru">Экспериментальное моделирование и лабораторная оценка адаптивных реакций организма / И.А. Волчегорский, И.И. Долгушин, О.Л. Колесников, В.Э. Ц ейликман. Челябинск: ЧелГПУ; 2000. 167 с.</mixed-citation><mixed-citation xml:lang="en">Экспериментальное моделирование и лабораторная оценка адаптивных реакций организма / И.А. Волчегорский, И.И. Долгушин, О.Л. Колесников, В.Э. Ц ейликман. Челябинск: ЧелГПУ; 2000. 167 с.</mixed-citation></citation-alternatives></ref><ref id="cit23"><label>23</label><citation-alternatives><mixed-citation xml:lang="ru">Львовская Е.И., Волчегорский И.А., Шемяков С.Е., Лифшиц Р.И. Спектрофотометрическое определение конечных продуктов ПОЛ. Вопросы медицинской химии. 1991;4:92–93.</mixed-citation><mixed-citation xml:lang="en">Львовская Е.И., Волчегорский И.А., Шемяков С.Е., Лифшиц Р.И. Спектрофотометрическое определение конечных продуктов ПОЛ. Вопросы медицинской химии. 1991;4:92–93.</mixed-citation></citation-alternatives></ref><ref id="cit24"><label>24</label><citation-alternatives><mixed-citation xml:lang="ru">Способ комплексной оценки содержания продуктов окислительной модификации белков в тканях и биологических жидкостях: метод. рекомендации / РИОязГМУ; сост.: М.А. Фомина. Рязань, 2014. 60 c.</mixed-citation><mixed-citation xml:lang="en">Способ комплексной оценки содержания продуктов окислительной модификации белков в тканях и биологических жидкостях: метод. рекомендации / РИОязГМУ; сост.: М.А. Фомина. Рязань, 2014. 60 c.</mixed-citation></citation-alternatives></ref><ref id="cit25"><label>25</label><citation-alternatives><mixed-citation xml:lang="ru">Viebahn-Haensler R., León Fernández O.S. Ozone in medicine. The low-dose ozone concept and its basic biochemical mechanisms of action in chronic inflammatory diseases. Int. J. Mol. Sci. 2021;22(15):7890. https://doi.org/10.3390/ijms22157890.</mixed-citation><mixed-citation xml:lang="en">Viebahn-Haensler R., León Fernández O.S. Ozone in medicine. The low-dose ozone concept and its basic biochemical mechanisms of action in chronic inflammatory diseases. Int. J. Mol. Sci. 2021;22(15):7890. https://doi.org/10.3390/ijms22157890.</mixed-citation></citation-alternatives></ref><ref id="cit26"><label>26</label><citation-alternatives><mixed-citation xml:lang="ru">Wang Z., Zhang A., Meng W. et al. Ozone protects the rat lung from ischemia-reperfusion injury by attenuating NLRP3-mediated inflammation, enhancing Nrf2 antioxidant activity and inhibiting apoptosis. Eur. J. Pharmacol. 2018;835:82–93. https://doi.org/10.1016/j.ejphar.2018.07.059.</mixed-citation><mixed-citation xml:lang="en">Wang Z., Zhang A., Meng W. et al. Ozone protects the rat lung from ischemia-reperfusion injury by attenuating NLRP3-mediated inflammation, enhancing Nrf2 antioxidant activity and inhibiting apoptosis. Eur. J. Pharmacol. 2018;835:82–93. https://doi.org/10.1016/j.ejphar.2018.07.059.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
